14
Index 2008 Index 2010# Companies Originators 18 20
# Companies Generic Manufacturers
2Same Index, adjusted
weights
7Separate Index, adjus
weights / KPIs
Diseases Scope*Includes Communicable & Non-Communicable Diseases
26Mortality-based
33Morbidity-based
Inc: NCD’s
Country Scope 88UN HDI 2006. Exclusions for WB’s ‘medium-high’ & ‘high’
Number of KPIs 28 106 (111)
Weight Adjustments Adjustments for single disease area co’s.
Based on Originator / Generic revenue streams
Products covered Predominantly Medicines Vaccines, diagnostics, new technologies & paediatrics
Access to Medicine Index Methodology Changes Between Index 2008 & Index 2010
Index 2008
Public Policy & Advocacy
R&D
Patents & Licensing
Capacity
Equitable Pricing
Donations
Philanthropy
ATM Management
3
Access to Medicine Index Methodology Structural Changes for Index 2010
Access to Medicine Index MethodologyEvolves in-line with Global Health Environment
Index 2008 Index 2010 2012
Stakeholder Review & Methodology Update Process
Significant Changes Incremental Changes
To adjust methods to changing global healthcare priorities To improve methodology based on learning from past indices
Data Collection ProcessWhere Does Our Data Come From?
Company Originated
Company Annual Report / SEC filings
Company CSR / Sustainability Docs
Company Websites / pages
Qualitative Questionnaire
Excel: R&D Pipeline
Excel: Product Portfolio
Third-Party Sources
Databases: Factiva/Lexis Nexus
Mulitlateral / G’ment Reports
Civil Society / NGO Reports
Academic Literature
Interviews with Partners (iNGO’s, PDPs, patent pool, donation orgs etc)
Media Databases (Index Country media)
Index Database
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Management
Public Policy and Market Influence
Research & Development
Equitable Pricing, Manufacturing & Distribution
Patents & Licensing
Capability Advancement Advancement in Product Development and Distribution
Product Donations & Philanthropic Activities
Index Structure: strategic driversCommitments
o Indicator of future performance o Robustness (detailed? with clear goals?
Supported by operational targets?)o Policy Stances – publicly available?
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Management
Public Policy and Market Influence
Research & Development
Equitable Pricing, Manufacturing & Distribution
Patents & Licensing
Capability Advancement Advancement in Product Development and Distribution
Product Donations & Philanthropic Activities
Index Structure: strategic driversTransparency
o Improving accountability to stakeholders (focus on public disclosure and quality of disclosure)
o Facilitate learning – focus on process disclosureo Improve internal company (and sector-wide) reporting
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Management
Public Policy and Market Influence
Research & Development
Equitable Pricing, Manufacturing & Distribution
Patents & Licensing
Capability Advancement Advancement in Product Development and Distribution
Product Donations & Philanthropic Activities
Index Structure: strategic driversPerformance
o “Ideally”, capturing the impact of companies on health burden “on the ground”.
o Remains to be the focus area of the Index for improvement & will gradually improve over time
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Management
Public Policy and Market Influence
Research & Development
Equitable Pricing, Manufacturing & Distribution
Patents & Licensing
Capability Advancement Advancement in Product Development and Distribution
Product Donations & Philanthropic Activities
Index Structure: strategic driversBusiness Model Innovation
o Focus on business model Innovation (‘new approaches’)o Uniquenesso Promise of impact or realised impacto Key strategic pillar for learning
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Management
Public Policy and Market Influence
Research & Development
Equitable Pricing, Manufacturing & Distribution
Patents & Licensing
Capability Advancement Advancement in Product Development and Distribution
Product Donations & Philanthropic Activities
Index Structure: Seven Technical AreasEach area has 2–3 sub-topics of focus
For example: 1. Advocacy and
Lobbying2. Competition
Behavior3. Marketing
Behavior
For example: 1. Innovative R&D2. Adaptive R&D3. Intellectual
Property Sharing
12
Technical Area
s
A. General Access to Medicine Management
ATM GovernanceATM Management System
Stakeholder Engagement
B. Public Policy and Market Influence
Advocacy and LobbyingCompetition BehaviorMarketing Behavior
C. Research and DevelopmentInnovative R&DAdaptive R&D
Intellectual Property Sharing
D. Equitable Pricing, Manufacturing and Distribution
Marketing Approval (Registration)Equitable Pricing
Manufacturing & Distribution
E. Patents & LicensingPatents
Non-Exclusive Voluntary Licensing
F. Capability Advancement in Product Development and Distribution
Capacity Building in Research and Development
Capacity Building in Quality Management and Distribution
G. Product Donations and Philanthropic Activities
Donations
Philanthropy
Access to Medicine Index Methodology Issue Focus of Technical Areas
13
For the analysis of all companies we always focus on the
depth and breadth of the companies ‘access’ initiatives:All approved products targeting Index Diseases – not just the flagship
programmes(portfolio analysis)All areas of R&D activity for eligible areas (pipeline analysis)
It is a relative index. Score of 5 indicates leading practice
compared with peers, score of zero indicates lagging
practice and 2.5 aims to reflect average practice.
Data Analysis ProcessThe bigger picture
14
